Search Results - "Samey, Benedicte"

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM) by Ades, Lionel, Guerci-Bresler, Agnes, Cony-Makhoul, Pascale, Legros, Laurence, Sebert, Marie, Braun, Thorsten, Delaunay, Jacques, Samey, Benedicte, Desseaux, Kristell, Chevret, Sylvie, Fenaux, Pierre

“…▪ Background: Although azacitidine (AZA) improves survival over conventional treatments in higher risk MDS (Lancet Oncol, 2009), median overall survival (OS)…”
Get full text

Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM) by Sebert, Marie, Stamatoullas, Aspasia, Braun, Thorsten, Delaunay, Jacques, de Renzis, Benoît, Jeddi, Ramzi, Meddeb, Balkis, Hunault Berger, Mathilde, Samey, Benedicte, Chermat, Fatiha, Chevret, Sylvie, Chaffaut, Cendrine, Fenaux, Pierre, Ades, Lionel

“…Background: Hypomethylating agents, especially AZA, have become the reference treatment of higher risk MDS, but the median survival of about 2 years obtained…”
Get full text

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM) by Ades, Lionel, Récher, Christian, Lejeune, Julie, Stamatoullas, Aspasia, Sebert, Marie, Delaunay, Jacques, Samey, Benedicte, Bouabdallah, Krimo, Braun, Thorsten, Vey, Norbert, Park, Sophie, de Renzis, Benoit, Chevret, Sylvie, Fenaux, Pierre

“…▪ Background: Higher risk MDS and AML with del(5q) carry very poor prognosis, but show some response to AZA and LEN as single agents (Adès Blood 2009,…”
Get full text

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment by Sebert, Marie, Bally, Cecile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, marie Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chaffaut, Cendrine, Sapena, Rosa, Samey, Benedicte, Chermat, Fatiha, Chevret, Sylvie, Ades, Lionel, Fenaux, Pierre

“…▪ Background: Hypomethylating agents (HMAs) have become the reference treatment of higher risk MDS, but the median survival of about 2 years obtained with AZA…”
Get full text

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients by Ades, Lionel, Guerci-Bresler, Agnès, Makhoul, Pascale Cony, Legros, Laurence, Delaunay, Jacques, Recher, Christian, Desseaux, Kristell, Samey, Benedicte, Chevret, Sylvie, Fenaux, Pierre

“…Although azacitidine (AZA) improves survival over conventional treatments in higher risk MDS (Lancet Oncol, 2009), median overall survival (OS) with AZA is…”
Get full text

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies by Ades, Lionel, de Renzis, Benoit, Jeddi, Ramzi, Delaunay, Jacques, Braun, Thorsten, Berger, Mathilde Hunault, Stamatoullas, Aspasia, Sanhes, Laurence, Samey, Benedicte, Chermat, Fatiha, Meddeb, Baklis, Fenaux, Pierre

“…Abstract 1720 hypomethylating agents, especially AZA, have become the reference treatment of higher risk MDS, but the median survival of about 2 years obtained…”
Get full text

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM) by Ades, Lionel, Prebet, Thomas, Stamatoullas, Aspasia, Recher, Christian, Guieze, Romain, Raffoux, Emmanuel, Bouabdallah, Krimo, Hunault, Mathilde, Wattel, Eric, Stalnikiewicz, Laure, Toma, Andrea, Dombret, Herve, Vey, Norbert, Gardin, Claude, Samey, Benedicte, Chevret, Sylvie, Fenaux, Pierre

“…Contrary to the “5q syndrome”, prognosis of higher risk MDS with del 5q, ie with increased marrow blast % and/or additional cytogenetic abnormalities (abn) and…”
Get full text

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM) by Ades, Lionel, Recher, Christian, Stamatoullas, Aspasia, Bouabdallah, Krimo, Delaunay, Jacques, Dreyfus, Francois, Vey, Norbert, de Renzis, Benoit, Raffoux, Emmanuel, Isnard, Françoise, Samey, Benedicte, Chaffaut, Cendrine, Chevret, Sylvie, Fenaux, Pierre

“…Higher risk MDS and AML with del(5q) carry very poor prognosis, but show some response to AZA and LEN as single agents (Adès et al. Blood 2009, Itzykson,…”
Get full text

Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with Acute Lymphocytic Leukemia Autografted during the First Remission by Gorin, Norbert C, Labopin, Myriam, Polge, Emmanuelle, Samey, Benedicte, Rocha, Vanderson

“…The cell source for autologous stem cell transplantation has shifted since 1994 from bone marrow (BM) to peripheral blood (PB). However, no study has compared…”
Get full text

Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT by Chevallier, Patrice, Labopin, Myriam, Cornelissen, Jan J., Socié, Gérard, Ljungman, Per T., Lioure, Bruno, Tilly, Herve, Gratwohl, Alois, Milpied, Noel, Yakoub-Agha, Ibrahim, Volin, Liisa, Vernant, Jean-Paul, Bay, Jacques-Olivier, Michallet, Mauricette, Buzyn, Agnès, Samey, Benedicte, Mohty, Mohamad, Rocha, Vanderson

“…Abstract 4558 Myeloid Sarcoma (MS) is a rare malignant disorder usually presenting as an extramedullary myeloid cell tumor proliferation. MS can be observed in…”
Get full text

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey by Nagler, Arnon, Labopin, Myriam, Shimoni, Avichai, Bunjes, Donald, Pimentel, Pedro, Socie, Gerard, Boudjedir, Karim, Zander, Axel R., Gomez, A. Torres, Baccarini, Michele, Goker, Hakan, Fassas, Athanasios, Kenzey, Chantal, Samey, Benedicte, Hamadi, Zouabi, Rocha, Vanderson

“…Oral Busulfan (Bu) is the historical backbone of pre-allogeneic stem cell transplantation (alloSCT) conditioning regimen. However, oral Bu has an erratic and…”
Get full text